Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Upgrade from Raymond James

Font: Financial Modeling Prep  • Jan 30, 2026

• Raymond James upgraded Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to an "Outperform" rating, raising the price target from $820 to $870.
• The company's Q4 2025 earnings call likely highlighted key financial metrics and strategic plans, supporting a positive future outlook.
• Despite a slight decrease in stock price to $741.45, Regeneron's market performance remains dynamic, with a significant market capitalization of approximately $76.58 billion.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicines. On January 30, 2026, Raymond James upgraded Regeneron to an "Outperform" rating, with the stock priced at $741.53. This upgrade came with an increased price target from $820 to $870, indicating confidence in the company's future performance.

Regeneron's recent Q4 2025 earnings call provided insights into its financial health and strategic plans. The call likely covered key metrics such as revenue and profit margins, as well as any significant developments or challenges. Executives would have shared guidance on future expectations, aligning with Raymond James' positive outlook.

Currently, Regeneron's stock is priced at $741.45, a slight decrease of 1.07% or $7.99. The stock has traded between $735.61 and $774.37 today, showing some volatility. Over the past year, it reached a high of $821.11 and a low of $476.49, reflecting its dynamic market performance.

Regeneron has a market capitalization of approximately $76.58 billion, highlighting its significant presence in the biotechnology sector. The trading volume for the day is 1,313,119 shares on the NASDAQ exchange, indicating active investor interest. This aligns with the recent upgrade and increased price target by Raymond James.